SME
IPO ·
BSE SME
Speciality Medicines Ltd
Listed
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat compl
Issue details
Price band
₹117 – ₹124
Face value
₹10
Lot size
1,000 shares
Minimum investment
₹2,48,000
Issue size
₹29.14 Cr
Fresh issue
₹27.28 Cr
Offer for sale
—
Issue type
Book Built
Exchange
BSE SME
Key dates
Opens
20 Mar 2026
Closes
24 Mar 2026
UPI mandate cut-off
5:00 PM on 24 Mar 2026
Allotment
25 Mar 2026
Refunds
27 Mar 2026
Shares in demat
27 Mar 2026
Listing
30 Mar 2026
Subscription and listing
Subscription
1.35x
Listing price
₹124
Registrar
Skyline Financial Services Pvt Ltd
Lead manager
Unistone Capital
Subscription by category
Total
1.35x
Total applications
661
Listing day
Issue price
₹124
Open
₹124.00
High
₹129.50
Low
₹124.00
Day close
₹125.90
Listing gain at open
0.00%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
21,000
0.89%
NII Shares Offered
10,89,000
46.34%
bNII > ₹10L
7,26,000
30.89%
sNII < ₹10L
3,63,000
15.45%
Retail Shares Offered
10,90,000
46.38%
Market Maker Shares Offered
1,50,000
6.38%
Total Shares Offered
23,50,000
100.00%
Finaccle’s quick read
Apply
FY25 income up 112%, PAT up 194%, ROE 18.11%, D/E 0.13, post-issue P/E 10.49x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets. The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations products, which are available in various dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
18.11%
ROCE
16.68%
Debt / equity
0.13
PAT margin
16.49%
P/E post issue
10.49
Market cap
₹108.94 Cr
Use of IPO money
Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat
₹12.68 Cr
Product Registration in International Markets and Product Development for sale in international markets
₹2.99 Cr
Funding for Marketing and Promotional Activities
₹1.66 Cr
To Meet Working Capital Requirements
₹8.00 Cr
General Corporate Purposes
₹0.25 Cr
Issue Expenses
₹3.57 Cr
Strengths
✓
Revenue up 112% in FY25 to ₹58.54 Cr
✓
PAT up 194% in FY25 to ₹8.61 Cr
✓
PAT margin of 16.49%
✓
ROE of 18.11% and ROCE of 16.68%
✓
Moderate leverage: debt to equity 0.13
Risks to watch
!
SME platform: large lot size and thinner trading liquidity
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.